Keyphrases
Chronic Kidney Disease
100%
Core Outcome Set
100%
Clinical Trials
79%
Sorafenib
50%
Risk Outcomes
50%
Patient Outcomes
50%
Risk-benefit
50%
Randomized Controlled Trial
50%
Patient Benefit
50%
Drug Development
50%
Web-based Survey
50%
Clinical Perspective
50%
Patient Risk
50%
FDA-approved Drugs
21%
Off-label Indications
21%
Trialists
18%
Adverse Events
14%
Approved Indication
14%
Monotherapy
14%
Objective Response Rate
14%
Literature Search
13%
Data Extraction
13%
International Consortium
12%
Health Measurement
12%
Health-related Quality of Life
12%
Health Outcomes
12%
Disease Research
11%
Overall Response Rate
7%
Differentiated Thyroid Carcinoma
7%
Excessive Risk
7%
Oncology Drugs
7%
Trial Characteristics
7%
New Indication
7%
Response Criteria
7%
Median Progression-free Survival
7%
Adverse Event Rates
7%
Bibliographic Databases
7%
Cancer Treatment
7%
Trends over Time
7%
Drug Trials
7%
Trial Participants
7%
Cancer Drugs
7%
Median Overall Survival
7%
Clinical Endpoints
7%
Pharmaceutical Companies
7%
Kidney Allograft Function
6%
Progressive Conditions
6%
Patient-reported Health
6%
Modality-specific
6%
Treatment Quality
6%
Medicine and Dentistry
Chronic Kidney Disease
100%
Clinical Trial
83%
Sorafenib
50%
Randomized Controlled Trial
50%
Adverse Event
21%
Malignant Neoplasm
14%
Health Outcomes
14%
Monotherapy
14%
Quality of Life
14%
Kidney Allograft
7%
Differentiated Thyroid Cancer
7%
Oncology
7%
Cancer Therapy
7%
Drug
7%
Drug Screening
7%
Overall Survival
7%
Progression Free Survival
7%
Transplantation
7%
Disease
7%
Informed Consent
6%
Inferential Statistics
6%
Potential Barrier
6%
Outcome Assessment
6%
Chi Square Test
6%
Prevalence
6%
Student T Test
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Clinical Trial
83%
Randomized Controlled Trial
50%
Sorafenib
50%
Drug Development
50%
Adverse Event
21%
Malignant Neoplasm
21%
Monotherapy
14%
Disease
7%
Differentiated Thyroid Cancer
7%
Overall Survival
7%
Progression Free Survival
7%
Drug
7%
Drug Screening
7%
Prevalence
6%